Amidst regulatory turmoil and a funding resurgence, companies provide insights on how they are navigating the changing ...

Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.

Biopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.

It's important to consider your comfort with risk before diving in.

Michael Yee, UBS global head of biotech research, joins 'Fast Money' to talk the biotech sector.

US lawmakers push Treasury to screen outbound biotech investments in China under the COINS Act. BINSA bill targets ...

VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro proof-of-concept data validating its ...

As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...

Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...

As the technology transforms scientific discovery, industry players are also grappling with the extent of its real-world use ...

While SpaceX dazzles with a $2 trillion valuation, Massachusetts’ biotech sector is quietly stacking wins that save lives and ...

Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR ...